Αποτελέσματα Αναζήτησης
5 Αυγ 2022 · This clinical practice guideline emphasizes the opportunities for primary prevention (eg, treatment to prevent isoimmune hemolytic disease, adequate breastfeeding support), the need to obtain an accurate history and physical examination to determine the presence of hyperbilirubinemia and hyperbilirubinemia neurotoxicity risk factors, the ...
- Hyperbilirubinemia
AAP Recommendations. In August 2022, the Academy released...
- Technical Report: Diagnosis and Management of Hyperbilirubinemia in the ...
Informed guidance on hyperbilirubinemia management,...
- Hyperbilirubinemia
Calculator and clinical decision support for the AAP 2022 guidelines for the management of hyperbilirubinemia in newborns 35 or more weeks of gestation. Features. Neurotoxicity risk factors absent, present, or both. Plot multiple time points to assess trends.
1 Σεπ 2022 · Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022 Sep 1;150 (3):e2022058859. doi: 10.1542/peds.2022-058859.
With improvements in medical equipment and medical technology, and growing concerns about the overtreatment of hyperbilirubinemia, the newest clinical practice guidelines attempt to tackle the prevention, risk assessment, monitoring, and treatment of hyperbilirubinemia with these things in mind.
AAP Recommendations. In August 2022, the Academy released updated clinical guidance on the prevention and treatment of hyperbilirubinemia in newborns greater than 35 weeks of gestational age. This clinical practice guideline will remain valid for use in practice through August of 2027 and considered retired thereafter.
This article updates and replaces the 2004 American Academy of Pediatrics (AAP) clinical practice guideline for the management and prevention of hyperbilirubinemia in the newborn infant $35 weeks’ gestation.3 This clinical practice guideline, like the previous one, addresses issues of prevention, risk assessment, monitoring, and treatment.
5 Αυγ 2022 · Informed guidance on hyperbilirubinemia management, including preventive treatment thresholds, is essential to safely minimize neurodevelopmental risk. OBJECTIVE.
